Diabetes – Top 5 Companies to Watch this Week

While a global pandemic is driving companies like Moderna Inc. to new highs, and Hertz Global Holdings to bankruptcy, it was only a few months ago, another epidemic – diabetes – dominated headlines. After all, diabetes is a severe chronic health issue, affecting more than 34 million in the U.S., or about 10% of the population. Fortunately, there are companies developing innovative nutrition, drug and medical devices to meet the growing needs of those with – or at risk of diabetes, including Glucose Health, Inc. (OTC: GLUC), MannKind Corporation (NASDAQ:MNKD), Insulet Corporation (NASDAQ:PODD), Becton, Dickinson and Company (NYSE:BDX), and Eli Lilly and Company (NYSE:LLY).

Glucose Health, Inc. (OTC: GLUC) BREAKING NEWS: Glucose Health, Inc. today announced that GLUCODOWN® – America’s premier diabetic nutritional beverage – will be available at CVS pharmacies beginning this summer. In keeping with CVS’s long-standing commitment to improving the health and well-being of its diabetic and pre-diabetic customers, CVS is updating and expanding the diabetic care section at many of its pharmacies. The expanded section will feature a specially curated selection of the finest products serving diabetic and pre-diabetic persons. All four nutritious and delicious GLUCODOWN® flavors – Peach, Lemon, Raspberry and Super Berry – will be stocked in CVS’s expanded diabetic care section.

The CVS product and supplier evaluation process is considered the most rigorous in the industry. GLUCODOWN® was required to complete the “Tested to be True” program, administered for CVS by NSF International. NSF International maintains and helped facilitate the development of NSF/ANSI 173, the only American National Standard for testing and certifying dietary supplements. CVS is unique among national pharmacy retailers in mandating independent third-party testing of dietary supplements, using the ANSI 173 standard. Random samples of GLUCODOWN® were provided to NSF International in late March and the (successful) test results were released simultaneously to CVS and Glucose Health, Inc., on May 5, 2020.

Murray Fleming, CEO of Glucose Health, Inc., stated, “70% of the population lives within 3 miles of a CVS pharmacy. Expanding GLUCODOWN® distribution with CVS, is the greatest leap forward we could make as a Company, to make it as convenient as possible for consumers to purchase GLUCODOWN® right in their neighborhood. We have already secured our CVS supplier number and established an electronic data interchange (EDI) link for receipt of purchase orders and issuance of invoices. I look forward to sharing even more details regarding this exciting CVS rollout, in the near future.”

Other related developments from around the markets include:

MannKind Corporation (NASDAQ:MNKD) reported financial results for the quarter ended March 31, 2020. “We are pleased to report first quarter Afrezza net revenue of $8.0 million, which is 58% higher than the same quarter in 2019,” said Michael Castagna, Chief Executive Officer of MannKind Corporation.  ”We believe that some of the increased revenue this quarter reflects the impact of patients stocking up on extra refills in advance of the stay-at-home orders that have since been implemented across the country.  In response to the COVID-19 pandemic, we have rapidly implemented digital tools and programs to help our sales force and our Afrezza prescribers navigate this challenging time for our healthcare system.  In addition, our manufacturing and development team in Connecticut remain focused on maintaining supply of Afrezza and meeting our obligations under our collaboration with United Therapeutics.”

Insulet Corporation (NASDAQ:PODD) announced financial results for the three months ended March 31, 2020. “Our thoughts are with all those affected by COVID-19 and our gratitude goes out to the medical professionals and first responders on the front lines during this unprecedented time,” said Shacey Petrovic, President and Chief Executive Officer. “I am proud of the way our employees have rapidly adjusted to the realities of the COVID-19 pandemic, responding with resilience and compassion and maintaining an unwavering focus on our mission to improve the lives of people with diabetes.” Ms. Petrovic continued, “Insulet entered 2020 with positive momentum, making progress toward our strategic objectives and achieving strong revenue growth ahead of expectations. The efficiency and redundancy we have built in our supply chain and manufacturing operations enabled us to meet customer demand without interruption during this challenging time. We believe that our proven, durable annuity business model will continue to generate double-digit revenue growth in 2020. We remain confident we have the right strategic framework to effectively advance our mission, drive sustainable long-term growth throughout our global business, and to continue to create shareholder value.”

Becton, Dickinson and Company (NYSE:BDX) reported quarterly revenues of $4.253 billion for the second fiscal quarter ended March 31, 2020.  This represents an increase of 1.4 percent as reported over the prior-year period, or 2.4 percent on a currency-neutral basis. "As the world responds to the COVID-19 pandemic, BD is focused on protecting the health and safety of our employees while addressing the critical health needs of our customers and their patients," said Tom Polen, CEO and president. "We are extremely proud of our team for their impact supporting healthcare providers on the front lines, launching several new diagnostic offerings to identify COVID-19 and ramping up production of essential medical devices. While our second quarter results were slightly ahead of our prior expectations, we are seeing the negative impact of coronavirus on certain parts of our business. We are confident that our diversified portfolio and the proactive actions we are taking will help us navigate these current challenges while positioning BD well as we continue to advance our long-term growth strategy."

Eli Lilly and Company (NYSE:LLY) announced baseline results from the GERAS-US Study examining the societal costs associated with mild cognitive impairment (MCI), mild dementia (MILD), and caring for someone with Alzheimer's disease (AD). The study, published today in The Journal of Alzheimer's Disease, is the first of its kind to show how early stages of cognitive decline economically impact both patients and caregivers. Alzheimer's is a relentless, fatal disease creating a health crisis for patients, families and society. Out of the top six diseases affecting Americans, AD is the only one with no treatment to prevent, cure or slow the disease. "It is well known that caregiver costs increase with disease severity and this study demonstrates that those costs are incurred even earlier than we expected, at the stage of mild cognitive impairment. Clearly, memory loss in a loved one is not a benign event," says Dorene M. Rentz, co-author, PsyD, Professor of Neurology at Harvard Medical School. "It has a detrimental impact on caregivers and families long before a diagnosis of AD dementia. This paper validates the importance of a timely diagnosis and reinforces the emerging science that treatment, even at the preclinical stage of disease, may benefit not only patients, but their caregivers as well." 

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Glucose Health Inc has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Glucose Health Inc. Please click here for full disclaimer.

Contact Information:
[email protected]